People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.